Northland Securities Comments on HRTX Q1 Earnings

Heron Therapeutics, Inc. (NASDAQ:HRTX) – Equities research analysts at Northland Securities issued their Q1 2026 earnings per share estimates for shares of Heron Therapeutics in a research report issued to clients and investors on Thursday, February 26th. Northland Securities analyst C. Byrnes forecasts that the biotechnology company will earn ($0.01) per share for the quarter. The consensus estimate for Heron Therapeutics’ current full-year earnings is ($0.13) per share. Northland Securities also issued estimates for Heron Therapeutics’ Q2 2026 earnings at ($0.01) EPS, Q3 2026 earnings at ($0.01) EPS and Q4 2026 earnings at $0.00 EPS.

A number of other research firms also recently weighed in on HRTX. HC Wainwright restated a “buy” rating and issued a $6.00 price target on shares of Heron Therapeutics in a research note on Friday, January 9th. Zacks Research downgraded shares of Heron Therapeutics from a “hold” rating to a “strong sell” rating in a report on Thursday. Jefferies Financial Group reiterated a “buy” rating on shares of Heron Therapeutics in a research note on Tuesday, November 4th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Heron Therapeutics in a research note on Thursday, January 22nd. Three equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, Heron Therapeutics presently has a consensus rating of “Hold” and an average price target of $4.50.

Heron Therapeutics Stock Performance

Shares of HRTX stock opened at $1.19 on Monday. The company’s fifty day simple moving average is $1.30 and its 200-day simple moving average is $1.27. The company has a quick ratio of 1.51, a current ratio of 2.48 and a debt-to-equity ratio of 10.59. Heron Therapeutics has a 12 month low of $1.00 and a 12 month high of $2.68. The firm has a market cap of $224.36 million, a PE ratio of -9.15 and a beta of 1.26.

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings results on Thursday, February 26th. The biotechnology company reported ($0.02) EPS for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.01. The firm had revenue of $40.59 million during the quarter, compared to the consensus estimate of $39.53 million.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of HRTX. Goldman Sachs Group Inc. boosted its holdings in shares of Heron Therapeutics by 57.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,028,678 shares of the biotechnology company’s stock valued at $2,263,000 after acquiring an additional 373,518 shares in the last quarter. Prospera Financial Services Inc bought a new position in Heron Therapeutics during the 2nd quarter worth approximately $103,000. Los Angeles Capital Management LLC raised its stake in Heron Therapeutics by 292.5% during the second quarter. Los Angeles Capital Management LLC now owns 266,128 shares of the biotechnology company’s stock worth $551,000 after buying an additional 198,325 shares during the last quarter. Monaco Asset Management SAM lifted its stake in shares of Heron Therapeutics by 12.5% in the 2nd quarter. Monaco Asset Management SAM now owns 1,080,000 shares of the biotechnology company’s stock valued at $2,236,000 after purchasing an additional 120,000 shares during the period. Finally, ProShare Advisors LLC lifted its stake in Heron Therapeutics by 23.4% in the second quarter. ProShare Advisors LLC now owns 31,368 shares of the biotechnology company’s stock valued at $65,000 after buying an additional 5,953 shares during the period. Institutional investors and hedge funds own 80.01% of the company’s stock.

Trending Headlines about Heron Therapeutics

Here are the key news stories impacting Heron Therapeutics this week:

• Positive Sentiment: Q4 results and company guidance: Heron reported Q4 revenue of $40.59M and EPS of ($0.02), both modest beats vs. Street estimates, and reported full‑year 2025 net revenue of $154.9M (65% YoY growth driven by ZYNRELEF and APONVIE). Management issued FY2026 net revenue guidance of $173–$183M and adjusted EBITDA guidance of $10–$20M — a clear near‑term commercial growth signal. Heron Press Release
• Positive Sentiment: HC Wainwright reiterates Buy and $6 target: Analyst B. Folkes continues to rate HRTX a Buy and models a multi‑year recovery to profitability (FY2027+), including an eventual FY2030 EPS of $0.55 — signaling meaningful upside from current levels if execution and product growth continue. (HC Wainwright research note)
• Neutral Sentiment: HC Wainwright near‑term modeling: The firm provided detailed Q1–Q4 2026 EPS estimates (Q1 -$0.03, Q2 -$0.02, Q3 -$0.01, Q4 $0.00) and a FY2026 consensus around -$0.13 — useful visibility but not an immediate catalyst. (HC Wainwright research note)
• Neutral Sentiment: Coverage and takeaways from the quarter are circulating: earnings call highlights and analyst write‑ups summarize the beat, commercial momentum, and guidance. These pieces help investors parse the quarter but largely echo the company release. Earnings Call Highlights Zacks Analysis WTOP Snapshot
• Negative Sentiment: Modest medium‑term EPS downgrades from HC Wainwright: The analyst trimmed FY2027, FY2028 and FY2029 EPS forecasts slightly (FY2027 to $0.14 from $0.15; FY2028 to $0.39 from $0.43; FY2029 to $0.44 from $0.48). Those cuts reduce some of the upside implied by prior estimates and may have tempered enthusiasm after recent share gains. (HC Wainwright research note)

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.